BriLife

BriLife
	The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Other names	Brilife
Routes of; administration	Intramuscular
ATC code	None;
Identifiers
CAS Number	2699603-14-8;

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.^[2]^[3]^[4]^[5] It was developed by the Israel Institute for Biological Research (IIBR).^[2]^[6]^[7] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.^[8]^[9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.^[10]^[4]

References

^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ ^a ^b Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. PMC 7778607. PMID 33408775.
^ Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 635337. doi:10.3389/fmolb.2021.635337. PMC 8082173. PMID 33937326.
^ ^a ^b Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. PMC 7789827. PMID 33422546.
^ Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. PMC 8219860. PMID 34179072.
^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
^ Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. PMC 7816887. PMID 33476760.
^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
^ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
^ Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. PMC 7745033. PMID 33328475.

External links

Scholia has a profile for BriLife (Q100694835).

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

[1] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[:0-2] Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. PMC 7778607. PMID 33408775.

[3] Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 635337. doi:10.3389/fmolb.2021.635337. PMC 8082173. PMID 33937326.

[:1-4] Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. PMC 7789827. PMID 33422546.

[5] Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. PMC 8219860. PMID 34179072.

[NCT04608305-6] Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov

[7] Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. PMC 7816887. PMID 33476760.

[8] Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.

[9] "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.

[10] Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. PMC 7745033. PMID 33328475.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]